These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 31933417)

  • 21. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
    Fan XM; Zhang J; Niu SH; Li KX; Song CZ
    Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer.
    Jeong SY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS; Lee YY
    J Ovarian Res; 2019 Dec; 13(1):1. PubMed ID: 31892329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific Regions, Rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and Survival in Advanced Epithelial Ovarian Cancer.
    Rosendahl M; Harter P; Bjørn SF; Høgdall C
    Int J Gynecol Cancer; 2018 Feb; 28(2):316-322. PubMed ID: 29324538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
    Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
    Bizzarri N; Marchetti C; Conte C; Loverro M; Giudice MT; Quagliozzi L; Distefano M; Chiantera V; Scambia G; Fagotti A
    Gynecol Oncol; 2022 Jun; 165(3):453-458. PubMed ID: 35397918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
    Falcone F; Scambia G; Benedetti Panici P; Signorelli M; Cormio G; Giorda G; Bogliolo S; Marinaccio M; Ghezzi F; Rabaiotti E; Breda E; Casella G; Fanfani F; Di Donato V; Leone Roberti Maggiore U; Greggi S
    Gynecol Oncol; 2017 Oct; 147(1):66-72. PubMed ID: 28716306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
    Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
    J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
    Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
    Goldberg RM; Kim SR; Fazelzad R; Li X; Brown TJ; May T
    Gynecol Oncol; 2022 Jan; 164(1):212-220. PubMed ID: 34756470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study.
    Giorda G; Gadducci A; Lucia E; Sorio R; Bounous VE; Sopracordevole F; Tinelli A; Baldassarre G; Campagnutta E
    J Ovarian Res; 2014 Jul; 7():72. PubMed ID: 25328074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of favorable survival after secondary cytoreductive surgery for recurrent endometrial cancer.
    Shikama A; Minaguchi T; Takao W; Hosokawa Y; Nishida K; Tasaka N; Akiyama A; Sakurai M; Ochi H; Satoh T
    Int J Clin Oncol; 2019 Oct; 24(10):1256-1263. PubMed ID: 31098693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
    Wu JL; Zhao J; Zhang HB; Zuo WW; Li Y; Kang S
    Gynecol Oncol; 2020 Oct; 159(1):270-276. PubMed ID: 32694063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
    Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Collaborative expertise of gynecological and surgical oncologists in managing advanced epithelial ovarian cancer.
    Nikiforchin A; Sardi A; King MC; Baron E; Lopez-Ramirez F; Falla-Zuniga LF; Barakat P; Iugai S; Pawlikowski K; Nieroda C; Campbell K; Ryu H; Diaz-Montes T; Gushchin V
    Eur J Surg Oncol; 2024 Feb; 50(2):107948. PubMed ID: 38183864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of diaphragm involvement in stage 3B/3C ovarian-tubal-peritoneal epithelial cancer patients and survival outcomes.
    Durmuş Y; İşçi Bostancı E; Duru Çöteli AS; Ünsal M; Kayıkçıoğlu F; Boran N
    Arch Gynecol Obstet; 2021 Jan; 303(1):241-248. PubMed ID: 32989507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.
    Eriksson AGZ; Graul A; Yu MC; Halko A; Chi DS; Zivanovic O; Gardner GJ; Sonoda Y; Barakat RR; Abu-Rustum NR; Leitao MM
    Gynecol Oncol; 2017 Aug; 146(2):263-267. PubMed ID: 28527673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimally invasive surgical staging for early stage ovarian cancer: A long-term follow up.
    Gallotta V; Jeong SY; Conte C; Trozzi R; Cappuccio S; Moroni R; Ferrandina G; Scambia G; Kim TJ; Fagotti A
    Eur J Surg Oncol; 2021 Jul; 47(7):1698-1704. PubMed ID: 33573854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
    Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.